Tooth pain, dental disease, and poor access to dental care adversely affect how children perform in school and are associated with increased school absences and missed parental days of work.
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
March 22nd 2023Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
2 Clarke Drive
Cranbury, NJ 08512